Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Scheinberg

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Expert Opinion on Investigational Drugs|November 4, 2000
Targeted therapies for the myeloid leukaemiasP Maslak, D Scheinberg
Seminars in Hematology|July 1, 1988
Monoclonal antibodies in the treatment of hematopoietic malignanciesA Houghton, D Scheinberg
Clinical Orthopaedics and Related Research|April 1, 1982
Degradative enzyme activity in isolated chondrocyte populationsR D Scheinberg, M G Ehrlich, L Lippiello, et al.
Leukemia|June 25, 1998
A phase I trial of a single high dose of idarubicin combined with high-dose cytarabine as induction therapy in relapsed or refractory adult patients with acute lymphoblastic leukemiaM A Weiss, P Drullinsky, P Maslak, et al.
Differentiation; Research in Biological Diversity|September 1, 1993
Cooperation between retinoic acid and phorbol esters enhances human teratocarcinoma differentiationJ M Kurie, P Brown, E Salk, et al.
The Journal of Bone and Joint Surgery. American Volume|December 1, 1980
Capitellocondylar total elbow arthroplastyF C Ewald, R D Scheinberg, R Poss, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1996
Cytarabine with high-dose mitoxantrone induces rapid complete remissions in adult acute lymphoblastic leukemia without the use of vincristine or prednisoneM Weiss, P Maslak, E Feldman, et al.
Leukemia|June 1, 1993
Severe toxicity limits intensification of induction therapy for acute lymphoblastic leukemiaM Weiss, P Telford, S Kempin, et al.
Nuclear Medicine and Biology|July 1, 1994
Current status of radioimmunotherapyS M Larson, C R Divgi, A Scott, et al.
Leukemia|February 20, 2003
Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195E Feldman, M Kalaycio, G Weiner, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Expert Opinion on Investigational Drugs|November 4, 2000
Targeted therapies for the myeloid leukaemiasP Maslak, D Scheinberg
Seminars in Hematology|July 1, 1988
Monoclonal antibodies in the treatment of hematopoietic malignanciesA Houghton, D Scheinberg
Clinical Orthopaedics and Related Research|April 1, 1982
Degradative enzyme activity in isolated chondrocyte populationsR D Scheinberg, M G Ehrlich, L Lippiello, et al.
Leukemia|June 25, 1998
A phase I trial of a single high dose of idarubicin combined with high-dose cytarabine as induction therapy in relapsed or refractory adult patients with acute lymphoblastic leukemiaM A Weiss, P Drullinsky, P Maslak, et al.
Differentiation; Research in Biological Diversity|September 1, 1993
Cooperation between retinoic acid and phorbol esters enhances human teratocarcinoma differentiationJ M Kurie, P Brown, E Salk, et al.
The Journal of Bone and Joint Surgery. American Volume|December 1, 1980
Capitellocondylar total elbow arthroplastyF C Ewald, R D Scheinberg, R Poss, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1996
Cytarabine with high-dose mitoxantrone induces rapid complete remissions in adult acute lymphoblastic leukemia without the use of vincristine or prednisoneM Weiss, P Maslak, E Feldman, et al.
Leukemia|June 1, 1993
Severe toxicity limits intensification of induction therapy for acute lymphoblastic leukemiaM Weiss, P Telford, S Kempin, et al.
Nuclear Medicine and Biology|July 1, 1994
Current status of radioimmunotherapyS M Larson, C R Divgi, A Scott, et al.
Leukemia|February 20, 2003
Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195E Feldman, M Kalaycio, G Weiner, et al.
Pageof 2